Family Legacy Inc. grew its position in Aflac Incorporated (NYSE:AFL – Free Report) by 4.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,607 shares of the financial services provider’s stock after buying an additional 107 shares during the period. Family Legacy Inc.’s holdings in Aflac were worth $270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of AFL. FMR LLC boosted its stake in shares of Aflac by 4.0% during the 3rd quarter. FMR LLC now owns 1,202,104 shares of the financial services provider’s stock worth $134,395,000 after acquiring an additional 45,745 shares during the period. CreativeOne Wealth LLC acquired a new stake in shares of Aflac during the 3rd quarter worth about $335,000. Financial Counselors Inc. boosted its holdings in shares of Aflac by 15.8% during the 3rd quarter. Financial Counselors Inc. now owns 6,147 shares of the financial services provider’s stock worth $687,000 after buying an additional 838 shares during the period. L.M. Kohn & Company acquired a new position in Aflac in the 3rd quarter valued at about $249,000. Finally, Erste Asset Management GmbH acquired a new stake in Aflac during the third quarter worth approximately $2,256,000. 67.44% of the stock is currently owned by institutional investors and hedge funds.
Aflac Stock Performance
Shares of Aflac stock opened at $109.71 on Monday. The company’s 50 day moving average price is $106.49 and its two-hundred day moving average price is $107.66. The firm has a market capitalization of $59.88 billion, a P/E ratio of 11.43, a P/E/G ratio of 3.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.08. Aflac Incorporated has a fifty-two week low of $79.31 and a fifty-two week high of $115.50.
Wall Street Analysts Forecast Growth
AFL has been the topic of a number of recent research reports. Evercore ISI lowered their target price on Aflac from $104.00 to $102.00 and set an “underperform” rating on the stock in a research note on Wednesday, December 4th. Morgan Stanley boosted their price objective on shares of Aflac from $98.00 to $105.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Keefe, Bruyette & Woods lowered their target price on shares of Aflac from $107.00 to $104.00 and set a “market perform” rating on the stock in a report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price target on Aflac from $90.00 to $94.00 and gave the company a “neutral” rating in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company dropped their price objective on Aflac from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Aflac has an average rating of “Hold” and a consensus price target of $103.36.
Read Our Latest Stock Analysis on Aflac
Insiders Place Their Bets
In other news, Director Charles D. Lake II sold 29,802 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the completion of the transaction, the director now directly owns 49,962 shares in the company, valued at $5,360,422.98. This trade represents a 37.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Moskowitz sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the director now owns 25,393 shares in the company, valued at $2,733,048.59. The trade was a 3.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
About Aflac
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Featured Stories
- Five stocks we like better than Aflac
- Roth IRA Calculator: Calculate Your Potential Returns
- Copper’s Surge: 3 Top Trades Before the Market Catches On
- Basic Materials Stocks Investing
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 03/24 – 03/28
Want to see what other hedge funds are holding AFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aflac Incorporated (NYSE:AFL – Free Report).
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.